Clinical trial · Observational
Quality of Life in Patients Undergoing Embolization Using Yttrium Y 90 Glass Microspheres for Primary or Metastatic Liver Cancer
A Quality of Life Study for Patients With Primary or Metastatic Liver Cancer Who Are Treated With Radioembolization (Y90 Microspheres) or Transcatheter Arterial Embolization (TACE)
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Learning about quality of life in patients with cancer undergoing embolization may help doctors learn about the side effects of treatment and plan the best treatment. PURPOSE: This clinical trial is studying quality of life in patients undergoing embolization using yttrium Y 90 glass microspheres for primary or metastatic liver cancer.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Liver Cancer | Malignant Liver Neoplasm | CURATED_EXACT | 0.92 |
| Metastatic Cancer | Malignant Neoplasm | CURATED_BROADER | 0.78 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (3)
- label
- Y90 Group
- description
- Patients receiving treatment with radioembolization.
- label
- TACE Group
- description
- Patients receiving treatment with transcatheter arterial embolization
- label
- RFA Group
- description
- Patients receiving treatment with radiofrequency ablation.
Primary outcomes (2)
- measure
- Quality of life of all patients over the course of treatment
- timeFrame
- Before treatment, 2 weeks post, and 1 month post
- measure
- Quality of life differences between treatment groups
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Diagnosis of primary hepatocellular cancer or metastatic liver cancer * Planning radioembolization or transcatheter arterial embolization using yttrium Y 90 glass microspheres * No encephalopathy PATIENT CHARACTERISTICS: * ECOG performance status 0-2 * Bilirubin ≤ 3 mg/dL * Able to comply with study procedures PRIOR CONCURRENT THERAPY: * No prior treatment with radioembolization or transcatheter arterial embolization
References
Publications (1)
- DERIVEDSalem R, Gilbertsen M, Butt Z, Memon K, Vouche M, Hickey R, Baker T, Abecassis MM, Atassi R, Riaz A, Cella D, Burns JL, Ganger D, Benson AB 3rd, Mulcahy MF, Kulik L, Lewandowski R. Increased quality of life among hepatocellular carcinoma patients treated with radioembolization, compared with chemoembolization. Clin Gastroenterol Hepatol. 2013 Oct;11(10):1358-1365.e1. doi: 10.1016/j.cgh.2013.04.028. Epub 2013 May 2. PMID 23644386